~ Buy the VIVJOA (oteseconazole) Drug Profile, 2024 PDF Report in the Report Store ~

VIVJOA Drug Patent Profile

Which patents cover Vivjoa, and what generic alternatives are available?

Vivjoa is a drug marketed by Mycovia Pharms and is included in one NDA. There are five patents protecting this drug.

This drug has sixty-three patent family members in twenty-two countries.

The generic ingredient in VIVJOA is oteseconazole. One supplier is listed for this compound. Additional details are available on the oteseconazole profile page.

DrugPatentWatch^® Generic Entry Outlook for Vivjoa

Vivjoa will be eligible for patent challenges on April 26, 2026. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 17, 2036. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for VIVJOA

International Patents:	63
US Patents:	5
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	25
Patent Applications:	36
Drug Prices:	Drug price information for VIVJOA
What excipients (inactive ingredients) are in VIVJOA?	VIVJOA excipients list
DailyMed Link:	VIVJOA at DailyMed

See drug prices for VIVJOA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for VIVJOA

NDA:

215888

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Anatomical Therapeutic Chemical (ATC) Classes for VIVJOA

J02AC	Triazole and tetrazole derivatives
J02A	ANTIMYCOTICS FOR SYSTEMIC USE
J02	ANTIMYCOTICS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

US Patents and Regulatory Information for VIVJOA

VIVJOA is protected by five US patents and two FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting VIVJOA

FDA Regulatory Exclusivity protecting VIVJOA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mycovia Pharms	VIVJOA	oteseconazole	CAPSULE;ORAL	215888-001	Apr 26, 2022		RX	Yes	Yes
Mycovia Pharms	VIVJOA	oteseconazole	CAPSULE;ORAL	215888-001	Apr 26, 2022		RX	Yes	Yes
Mycovia Pharms	VIVJOA	oteseconazole	CAPSULE;ORAL	215888-001	Apr 26, 2022		RX	Yes	Yes			Y	Y
Mycovia Pharms	VIVJOA	oteseconazole	CAPSULE;ORAL	215888-001	Apr 26, 2022		RX	Yes	Yes
Mycovia Pharms	VIVJOA	oteseconazole	CAPSULE;ORAL	215888-001	Apr 26, 2022		RX	Yes	Yes			Y	Y

International Patents for VIVJOA

When does loss-of-exclusivity occur for VIVJOA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

Denmark

Eurasian Patent Organization

European Patent Office

Hungary

Lithuania

Mexico

Poland

Portugal

Serbia

Slovenia

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VIVJOA around the world.

Country	Patent Number	Title	Estimated Expiration
China	103097374	Metalloenzyme inhibitor compounds
Hungary	E026474
Serbia	63566	ANTIFUNGALNA JEDINJENJA I PROCESI IZRADE (ANTIFUNGAL COMPOUNDS AND PROCESSES FOR MAKING)
Portugal	3271347
Denmark	3271347